Financial Performance - In the first half of 2024, the company achieved operating revenue of 236 million yuan, a year-on-year increase of 20.14% [2] - The net profit attributable to shareholders was 30 million yuan, up 912.89% year-on-year [2] - The basic earnings per share reached 0.23 yuan, reflecting a year-on-year growth of 1,050% [3] - In Q2 2024, operating revenue was 137 million yuan, with a quarter-on-quarter increase of 40.39% [3] Market Demand and Challenges - The demand for life science materials has rebounded compared to the same period last year, driven by downstream users such as universities, hospitals, and biopharmaceutical companies [3] - The global economic downturn, geopolitical conflicts, and trade barriers continue to pose challenges to the market [3] - Despite external pressures, the company is expanding its product line and improving service levels to enhance competitiveness [3] Cost Management and Efficiency - The company has effectively controlled raw material procurement costs despite rising prices [3] - Measures include establishing subsidiaries for in-house production of packaging materials, which helps reduce costs [3] - The overall expense ratio decreased by 2.83 percentage points compared to the same period last year, with a gross margin of 38.08% in the first half of 2024, up 11.60 percentage points year-on-year [3] International Expansion and Brand Development - The company has built a brand team and is promoting its products through social media and local offices [5] - It has adopted a "local service for local needs" strategy by establishing overseas subsidiaries and hiring local sales personnel [5] - The company is preparing for potential overseas production to mitigate trade risks, although it is cautious due to uncertainties in the political landscape [5] Future Outlook - The company expects continued growth in both domestic and international markets, with a focus on enhancing product quality and brand strength [4] - The second half of the year is anticipated to see a seasonal dip in sales due to summer vacations, but overall market demand is expected to be better than last year [4] - The company plans to optimize cost control and production processes to further improve profitability [5]
洁特生物(688026) - 投资者关系活动记录表(2024年8月26日)